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INTRODUCTION
Both inflammation and structural changes may occur in aller-
gic rhinitis (AR), and chronic eosinophilic inflammation is re-
lated to the development of remodeling.
1 Remodeling is char-
acterized by epithelial fragility, reticular basement membrane 
thickening, and an increase in vascularity, the number of fibro-
blasts, and interstitial collagen as well as mucous gland hyper-
trophy.
2 Remodeling appears to be less extensive in the nose 
than in the lower airways because of the differences in the se-
cretory activity of smooth muscle cells that are present in the 
bronchi but not in the nose. The different embryologic origins 
of the bronchi and nose may also account for the differences in 
the extent of remodeling between different airway regions.
3 
Knowledge of fibrogenic growth factors in the nasal mucosa of 
AR patients is lacking because of the paucity of studies on AR 
compared to asthma.
4 Periostin (formerly called osteoblast-spe-
cific factor 2) was originally identified as a secreted factor in a 
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screen of a mouse osteoblastic library. It is thought to function 
in bone adhesion, because its sequence is similar to that of an 
insect adhesion protein, fasciclin-1, and because it is expressed 
in specialized connective tissues that form and support miner-
alized tissue.
5 This protein is induced by interleukin (IL)-4 and 
IL-13 in airway epithelial cells.
6,7 Periostin also shares structural 
homology to other mammalian proteins, including big-h3, sta-
bilin I and II, MBP-70, algal-cell adhesion molecule, and peri-
ostin-like factor.
8-12 To date, many studies on periostin have fo-
cused on its role in extracellular matrix deposition, fibrosis, and 
tissue remodeling following myocardial infarction, as well as its 
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Purpose:  Periostin was originally identified as a secreted factor during screening of a mouse osteoblastic library. In a recent study, periostin was 
found to directly regulate eosinophil accumulation in allergic mucosal inflammation. Chronic eosinophilic inflammation is related to the development 
of remodeling. The present study examined the expression of periostin and evaluated its role in the inflammatory process and remodeling associat-
ed with allergic rhinitis.  Methods:  A murine model of allergic rhinitis was established in periostin knockout mice. We analyzed the expression of 
periostin, manifestation of nasal symptoms, eosinophilic inflammation, and subepithelial fibrosis as well as the expression of MMP-2, TIMP-1, and 
type 1 collagen in nasal tissue.  Results:  Periostin was mainly distributed in the subepithelial tissue of the nasal mucosa. The subepithelial tissue 
was thinner in the knockout group than in the control group. No differences in the expression of MMP-2 or TIMP-1 were found in the knockout group. 
However, after a month of allergen challenge, type I collagen in the nasal tissue was lower in the knockout group than in the control group. The num-
ber of eosinophils and the symptom score were also lower in the knockout group.  Conclusions:  Periostin is expressed in nasal tissues of murine 
models of allergic rhinitis. Periostin deficiency may affect the remodeling of nasal tissue with reduced subepithelial fibrosis, and lead to less eosino-
philic inflammation.
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involvement in stimulating metastatic growth of cancer cells by 
promoting cell survival, invasion, and angiogenesis.
5,13-17 How-
ever, there have been only a few studies on periostin in relation 
to allergy, despite the common features of extensive tissue re-
modeling seen in both heart failure after myocardial infarction 
and allergic inflammation of airways. One previous study fo-
cused on the role of periostin in allergic eosinophilic inflamma-
tory disease (eosinophilic esophagitis) involving extensive tis-
sue remodeling, extending the known involvement of periostin 
to allergic esophagitis and proposing a novel role for periostin 
in the direct regulation of eosinophil accumulation in T helper 
type 2 (Th2)-associated mucosal inflammation of both mice 
and humans.
18 The present study examined the expression of 
periostin in airway remodeling in a murine model of AR and 
evaluated the roles of periostin in rhinitis symptom manifesta-
tion, the inflammatory process, and airway remodeling associ-
ated with AR using periostin knockout mice.
MATERIALS AND METHODS
Mice and allergic rhinitis model
Mice
B6;129-Postn
tm1Jmol/J mice (targeted mutation of periostin) 
were purchased from the Jackson Laboratory (Bar Harbor, ME, 
USA). Male C57BL/6J mice (4 weeks of age; the control strain 
for the B6;129-Postn
tm1Jmol/J mice recommended by the compa-
ny) were obtained from Koatech Laboratory Animal, Inc. (Py-
eongtaek, Korea). Homozygotes were used for experiments 
among the offspring generated from mating female heterozy-
gotes and male homozygotes of the B6;129-Postn
tm1Jmol/J mice, 
according to the manufacturer’s directions. All mice were 
housed in an air-conditioned room maintained at 22-24°C and 
50%-60% humidity. All of the animal experiments were approved 
by the Animal Research Ethics Board of Gyeongsang National 
University.
Immunization of mice and nasal challenge
Ovalbumin (OVA; Sigma, St. Louis, MO, USA)-induced airway 
inflammation was performed in mice as described previously.
19 
Male mice (C57BL/6J or B6;129-Postn
tm1Jmol/J) at 4 weeks of age 
were sensitized by intraperitoneal injection of 25 µg OVA/2 mg 
aluminum hydroxide gel on days 0 and 5, followed by daily in-
tranasal challenge (from day 12 to day 19) with 3% OVA diluted 
in 40 µL phosphate buffered saline (PBS). Prolonged inflam-
mation was induced by subsequent nasal exposure to 3% OVA 
three times a week after day 19 until the mice were sacrificed 
after 1 or 3 months. The B6;129-Postn
tm1Jmol/J strain mice were 
called the KO group, and the C57BL/6J strain mice were called 
the OVA group. Data were obtained from five mice per group. 
The control mice (C57BL/6J) received saline injections and sa-
line intranasal challenges instead of the OVA solution and were 
called the PBS group (Fig. 1).
Evaluation of allergen-induced nasal symptoms
Nasal symptoms were recorded by counting the number of 
sneezes and nasal scratching motions (nasal rubbing) that oc-
curred for 10 minutes after the last allergen challenge. Exami-
nations were performed at day 19 and at months 1 and 3. The 
observers were blinded to the behaviors.
Fig. 1.  Protocol for induction of the murine AR model. Three groups of mice were used in these experiments, and each group contained three subgroups, according 
to the day of sacrifice.
PBS, phosphate buffered saline; OVA, ovalbumin; KO, knockout; W, week; M, month.
  0  5  12  19  26  33  47  103 days
  1W  2W  4W (1M)  12W (3M)
Intraperitoneal injection of  25 µg OVA / 2 mg of aluminum hydroxide gel
Intranasal challenge with  3% OVA 
Sacrifice and Sampling
OVA / KO Groups (n=15 )
Intraperitoneal injection of  PBS
Intranasal challenge with  PBS 
Sacrifice and Sampling
PBS Group (n=15 )Hur et al.
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Preparation for histology
The experimental mice were sacrificed and decapitated after 
being anesthetized by an intraperitoneal injection of Zoletil
® 
(tiletamine/zolazepam; Virbac, Carros Cedex, France). The 
heads were fixed in 2% paraformaldehyde and decalcified in 5% 
nitric acid for 5 days at 4°C. Then the heads were embedded in 
paraffin. The paraffin-embedded nasal cavity was transversely 
sectioned from the second palatal ridge to the first upper molar 
tooth at a thickness of 4 µm. Then the specimens were deparaf-
finized and stained with hematoxylin-eosin to evaluate general 
morphology.
Evaluation of the inflammatory process and remodeling
Eosinophils
Sirius red staining was used to visualize eosinophils. Eosino-
phils were counted in 10 different areas with a constant muco-
sal length on the slides under a high-power field (×400).
Subepithelial thickness
Specimens were also stained with Masson’s trichrome to visu-
alize collagen distribution in the nasal mucosa. Three coronal 
sections that were similar to the sinus cavity were chosen for 
evaluation. Subepithelial collagen thickness was quantified in 
10 different areas at random using an NIS-Elements BR 3.0 sys-
tem (Nikon Eclipse, Tokyo, Japan).
Type I collagen expression in the KO group
Immunohistochemical detection of type I collagen in the na-
sal tissue of the KO group was performed on 4.5-µm sections 
that were mounted on silicon-coated glass slides using a strep-
tavidin-biotin peroxidase technique, as described previously.
20
Quantitative analysis of matrix metalloproteinase 2, tissue 
inhibitor of metalloproteinase 1, and type I collagen by Western 
blotting
Nasal mucosal tissue lysates from five mice per group were 
extracted and subjected to Western blot analysis. Protein (30 μg) 
was subjected to electrophoresis in 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) gels and trans-
ferred to nitrocellulose membranes. After blocking in Tris-buff-
ered saline/5% milk, the membrane was incubated with rabbit 
anti-mouse matrix metalloproteinase 2 (MMP-2) antibody (Ab-
cam, Cambridge, UK) at a concentration of 1 μg/mL, a rabbit 
anti-mouse tissue inhibitor of metalloproteinase 1 (TIMP-1) 
antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 
1:200 dilution, and rabbit anti-mouse type I collagen antibody 
(Abcam, Cambridge, UK) at 1:5,000 dilution, followed by goat 
anti-rabbit IgG horse radish peroxidase (HRP)-conjugated anti-
body (1:5,000). Enhanced chemiluminescence was used for au-
toradiography.
Identification of periostin expression in nasal tissue
Immunohistochemistry
Immunohistochemical detection of periostin in nasal tissue 
was performed on 4.5-µm sections that were mounted on sili-
con-coated glass slides using a streptavidin-biotin peroxidase 
technique, as described previously.
20
Measurement of serum periostin levels
The blood samples were treated using the method outlined 
above. Quantitative assessment of periostin in serum was con-
ducted using an enzyme linked immunosorbent assay (ELISA) 
kit from R&D Systems Inc. (Minneapolis, MN, USA). All of the 
procedures were performed according to the manufacturer’s 
instructions. The serum samples were diluted 500-fold for the 
assay.
Statistical analysis
The data are presented as mean±standard error of the mean 
(SEM). The significance of the results was calculated using non-
parametric two-sided Mann-Whitney statistical tests for com-
paring two groups and the Kruskal-Wallis test for comparing 
multiple subgroups. Statistical analysis was performed using 
SPSS 12.0 (SPSS Inc., Chicago, IL, USA) software. A P value of 
<0.05 was considered significant.
RESULTS
Identification of periostin in the AR model
Immunohistochemical staining was performed to determine 
the expression of periostin and its localization in the nasal tis-
sue of AR mice. Periostin was mainly distributed in the subepi-
thelial tissue of the nasal mucosa as well as the pseudostratified 
columnar epithelium in the OVA group after 3 months of aller-
gen challenge (Fig. 2). The area in which periostin was expressed 
nearly overlapped with the area that was stained by Masson’s 
trichrome. Except for periosteal or perichondrial staining, areas 
positively stained for periostin were not identified in the KO 
and PBS groups.
Serum periostin was found in the PBS and OVA groups. How-
ever, serum periostin levels were not significantly different in 
the PBS or OVA groups over time. None was found in the KO 
group, and levels were constant in all groups despite the pres-
ence of a nasal allergic response (Fig. 3).
Evaluation of the remodeling and inflammatory processes
Fig. 4 shows changes in the thickness of the subepithelial tis-
sue of the nasal mucosa. It was significantly thinner in the KO 
group than in the OVA group (P<0.05), in which it increased 
gradually and peaked at 3 months (P<0.05).
Collagen deposition is an important pathological feature of 
subepithelial fibrosis. The presence of type I collagen in the na-
sal tissue of the KO group was determined using immunohisto-Roles of Periostin in Allergic Rhinitis
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chemistry (Fig. 5). Despite the deficiency of periostin, type I 
collagen was expressed around the subepithelial area as a ma-
trix protein of subepithelial fibrosis. Immunoblotting was per-
formed to evaluate the quantity of type I collagen expression in 
the nasal mucosa of different groups (Fig. 5). The KO group 
showed less type I collagen expression after 1 and 3 months of 
allergen challenge than the OVA group.
To evaluate the mechanism of reduced tissue remodeling in 
the KO group, the expression of MMP-2 and TIMP-1, which are 
well-known enzymes expressed during tissue remodeling and 
fibrosis in the nasal mucosa, were checked by immunoblotting 
(Fig. 6). There were no significant differences in the expression 
of MMP-2 or TIMP-1 in the nasal mucosa between the KO and 
OVA groups over time.
The proinflammatory functions and the important role of eo-
sinophils in chronic allergic diseases have been clearly eluci-
dated.
21 To determine whether periostin deficiency affects the 
tissue infiltration of eosinophils, these cells were counted in the 
histology slides after staining with Sirius red dye. The number 
of eosinophils in the nasal mucosa was significantly lower in 
the KO group than in the OVA group (P<0.05; Fig. 7). The OVA 
and KO groups showed significantly increased numbers of eo-
sinophils in the nasal mucosa compared to the PBS group, 
which showed few eosinophils in the nasal mucosa (P<0.05). In 
the OVA group, the eosinophil count increased after 3 months 
of allergen challenge when compared to the previous time 
Fig. 2.  Periostin immunohistochemistry. Images show the nasal respiratory mucosa after 3 months of allergen challenge. (A) OVA group, original magnification, ×
20. (B) OVA group, original magnification, ×400. (C) PBS group, original magnification, ×400. (D) KO group, original magnification, ×400. Periostin was highly ex-
pressed in the subepithelial area in the OVA group (asterisk in B). However, it was less expressed in the same area of the PBS group, and no periostin expression 
was observed in the KO group.
PBS, phosphate buffered saline; OVA, ovalbumin; KO, knockout.
A B C D
Fig. 3.  Periostin levels in serum. Serum periostin levels were not significantly 
different in the PBS or OVA groups over time. After 19 days, 1 month, and 3 
months of allergen challenge, the PBS and OVA groups showed similar serum 
periostin levels. Serum periostin was not found in the KO group. Data are ex-
pressed as mean±SE.
PBS, phosphate buffered saline; OVA, ovalbumin; KO, knockout.
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Fig. 4.  Subepithelial thickness of the nasal mucosa. The subepithelial thick-
ness of the nasal mucosa was measured (yellow arrow). (A) The nasal tissue 
around the septal cartilage in the PBS group after 3 months of allergen chal-
lenge (Masson’s trichrome staining, original magnification, ×400). (B) The 
same area in the OVA group after 3 months of allergen challenge. (C) The same 
area in the KO group after 3 months of allergen challenge. (D) The subepithelial 
tissue was thinner in the KO group than in the OVA groups. *P<0.05. The sub-
epithelial thickness increased over time in the OVA group. **P<0.05. Data are 
expressed as mean±SE.
PBS, phosphate buffered saline; OVA, ovalbumin; KO, knockout.
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points (P<0.05).
Manifestation of allergen-induced nasal symptoms
Sneezing and nose rubbing, predominant features in this 
model after allergen challenge, were used as symptom parame-
ters for AR. Fig. 8 shows the changes in allergen-induced nasal 
symptoms. The number of sneezes was lower in the KO group 
than in the OVA groups after 1 and 3 months of allergen chal-
lenge (P<0.05). The number of rubbings was lower in the KO 
group than in the OVA groups after 3 months of allergen chal-
lenge (P<0.05). The average numbers of sneezes and rubbings 
were higher in the OVA group than the PBS group at all record-
ed time points (P<0.05), and the numbers gradually increased 
over time. The average number of sneezes seemed higher in the 
PBS group than the KO group, and rubbings showed the oppo-
site pattern, although this was statistically nonsignificant. The 
allergen-induced nasal symptoms were maintained during the 
prolonged allergen challenge.
DISCUSSION
Remodeling occurs in the nasal mucosa of AR patients,
22,23 al-
though it appears that remodeling in the nose is less extensive 
than in the lungs.
4 One of the aims of this study was to establish 
a model of acute AR as well as a model of prolonged allergen-
induced nasal airway inflammation to mimic the tissue remod-
eling that is observed in chronic AR. We focused on subepithe-
lial fibrosis of the nasal mucosa, which increased after prolonged 
nasal mucosa allergen exposure in the OVA group. The pseudo-
thickening of the reticular basement membrane caused by col-
lagen and fibrous protein deposition occurred as a result of re-
modeling both in the bronchial and nasal mucosa, although 
the extent of pseudothickening was different between the two 
mucosal tissues.
2
Subepithelial fibrosis is the most prominent finding in pa-
tients with eosinophilia and severe disease.
24 It is also thought 
to change the mechanical properties of the airway wall, alter 
the folding behavior of the airway mucosa, heighten bronchial 
reactivity or narrow the airway, and reduce airflow.
25,26 Multiple 
cytokines, growth factors, and adhesion molecules, including 
IL-13 and TGF-β, have been implicated in the pathophysiology 
of subepithelial fibrosis in asthma.
27,28 In this study, the subepi-
A B
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Fig. 5.  Expression of type I collagen in the KO group visualized by immunohis-
tochemistry. (A) Original magnification, ×20. (B) Original magnification, ×400. 
Type I collagen was identified in the subepithelial tissue (asterisk in B) of the 
nasal mucosa, regardless of periostin deficiency. The graph depicts the ratio of 
collagen type I to β-actin from nasal tissue lysates. The KO group showed a 
trend toward decreased type I collagen expression after 1 and 3 months of al-
lergen challenge compared to the OVA group by immunoblotting. Two repre-
sentative results of immunoblotting (n=5) over time are shown.
OVA, ovalbumin; KO, knockout.
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Fig. 6.  MMP-2 and TIMP-1 expression in the nasal mucosa. The KO and OVA 
groups showed no significant differences in MMP-2 or TIMP-1 expression in 
the nasal mucosa by immunoblotting over time. MMP-2, matrix metalloprotein-
ase 2; TIMP-1, tissue inhibitor of metalloproteinase. Two representative results 
of immunoblotting (n=5) over time are shown.
OVA, ovalbumin; KO, knockout.Roles of Periostin in Allergic Rhinitis
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Fig. 7.  Eosinophil counts in the nasal mucosa. The nasal tissue around 
conchal cartilage in the OVA group after (A) 19 days, (B) 1 month, and (C) 
3 months are shown. Eosinophils are reddish (arrow). The nasal tissue 
of the KO group after (D) 19 days, (E) 1 month, and (F) 3 months are also 
shown (Luna staining, original magnification, ×400). (G) The number of 
eosinophils in the nasal mucosa was significantly lower in the KO group 
than in the OVA groups. *P<0.05. In the OVA group, the number of eo-
sinophils was higher at 3 months of allergen challenge than at the other 
time points. **P<0.05. Data are expressed as mean±SE.
HPF, high power field.
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Fig. 8.  Allergen-induced nasal symptoms. The numbers of (A) sneezes and (B) rubbings for 10 min immediately after the allergen challenge were counted. The OVA 
group had a higher symptom score than the PBS group at all time points, *P<0.05; The KO group had a lower sneeze score than the OVA group at 1 and 3 months of 
allergen challenge. The KO group had a lower rubbing score than the OVA group at 3 months of allergen challenge, **P<0.05. Data are expressed as mean±SE.
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thelial tissue in the nasal mucosa was significantly thinner in 
the KO group than in the OVA groups. These results suggest that 
periostin deficiency may decrease subepithelial fibrosis. Three 
possible mechanisms for this are proposed. First, periostin it-
self is the main extracellular matrix protein expressed particu-
larly in the regeneration process. Using this chronic AR model, 
periostin expression was identified in the subepithelial space of 
the nasal mucosa. Periostin was expressed during the early pe-
riod of the AR model, and its expression increased with the 
chronicity of allergen exposure. Serum periostin levels were not 
significantly different in the PBS or OVA groups over time, and 
they were not distinctly increased after a 3-month challenge 
with the allergen. This suggests that the expression of periostin 
in this AR model might be limited to the nasal tissue. Periostin 
is a novel tissue component that is involved in subepithelial fi-
brosis in bronchial asthma
6 and is also expressed in esophageal 
biopsies of eosinophilic esophagitis patients.
18 The periostin ex-
pression in the chronic AR model used in this study is consis-
tent with results seen in previously studied allergic diseases, 
and this is the first description of periostin expression in a chron-
ic AR model. Therefore, periostin deficiency in the KO group 
may be the reason for the decreased subepithelial fibrosis in 
these mice. Second, periostin deficiency could affect epithelial 
mesenchymal interactions for remodeling. A previous study of 
human bronchial epithelial cells and fibroblasts demonstrated 
that periostin secreted by airway epithelial cells has autocrine 
effects, including the activation of TGF-β and up-regulation of 
type I collagen, as well as paracrine effects, including a TGF-β-
mediated increase in type I collagen production in fibroblasts.
29 
Periostin also up-regulates MMP-2 and MMP-9 in an autocrine 
manner to activate TGF-β, leading to up-regulation of collagen 
in airway epithelial cells and fibroblasts. Changes in MMP-2 
and TIMP-1 were not identified in the periostin KO group in 
this study. Further studies are needed to determine the effect of 
periostin deficiency on the epithelial-mesenchymal unit. Eo-
sinophilic inflammation may be the third mechanism. Recent 
reports have supported a potential role for eosinophils in the 
development of airway remodeling.
30-32 Increased eosinophils 
in the bronchial mucosa of severe asthmatics have been associ-
ated with basement membrane thickening,
33 and eosinophils 
are capable of secreting an array of profibrotic mediators.
34,35 In 
a study using eosinophil-deficient mice, reduced subepithelial 
fibrosis was independent of TGF-β expression.
1 Reduced eosin-
ophil infiltration in the KO group may be another cause of the 
decreased subepithelial fibrosis. Fibrosis still occurs in the peri-
ostin KO group with other extracellular matrix proteins, like 
type I collagen, and periostin-null mice show aberrant type I 
collagen fibrillogenesis in the skin and poor integrity of the 
periodontal ligament in response to mechanical stress.
35 In the 
present study, the KO group showed decreased type I collagen 
expression after 1 and 3 months of allergen challenge com-
pared to the OVA group. These findings suggest that decreased 
subepithelial fibrosis in periostin deficiency may not be attrib-
uted to the absence of type I collagen and that decreased sub-
epithelial fibrosis might be related to decreased collagen pro-
duction.
Periostin was originally identified as a gene expressed in a 
mouse osteoblastic cell line
36; however, its pathophysiological 
roles remain poorly understood. It has been suggested that 
periostin plays a role in the development of bone, tooth, heart, 
and myoseptum.
8,37,38 Periostin is involved in the pathogenesis 
of heart failure and carcinogenesis.
13,39 Recently, there have 
been some reports about the effects of periostin in allergic in-
flammation. In a study of eosinophilic esophagitis, periostin di-
rectly regulated eosinophil accumulation in Th2-associated 
mucosal inflammation in both mice and humans.
18 Periostin 
derived from fibroblasts or epithelial cells has been considered 
a mediator of inflammation and fibrosis in allergic diseases.
6,18,30 
However, few studies have demonstrated a pathophysiological 
role of periostin in nasal tissues or AR, which are highlighted by 
the findings in the present study.
The role of periostin in the inflammatory process of AR was 
evaluated in our experiments by observing the effect of perios-
tin deficiency on a chronic AR model using periostin knockout 
mice. AR symptoms and eosinophil counts in nasal tissue were 
lower in knockout mice challenged by the allergen. These results 
suggest that periostin may affect or regulate the allergic response, 
and extend the findings of recent studies showing that eosino-
phil accumulation in the lung and esophagus decrease in aller-
gen-challenged periostin-deficient mice compared to wild-type 
mice.
18,40 It has been supposed that eotaxin-3 in the epithelium 
attracts eosinophils and that periostin increases the adhesion 
of eosinophils from the vessel to the lamina propria.
18 The de-
crease in symptoms after 1 month of allergen challenge in the 
KO group might be due to reduced eosinophilic inflammation 
and non-specific nasal hyperreactivity. These results suggest 
that periostin deficiency might reduce AR symptoms in the 
chronic AR model.
One of the limitations of this study in explaining the effect of 
periostin on chronic AR is the relationship of AR to inflamma-
tory mediators. In a previous study on periostin deficiency and 
allergic airway inflammation, the production of Th2 cytokines 
IL-4, IL-5, and IL-13 in bronchoalveolar lavage (BAL) fluid, 
splenocytes, and mediastinal lymph node cultures increased 
following stimulation with anti-CD3 or OVA from cultures of 
periostin-deficient cells, compared to wild-type cells.
41 This 
study suggested that periostin deficiency could enhance Th2 
inflammatory mediators in allergic airway inflammation.
The mechanisms of AR have been clarified by performing na-
sal challenge with allergen or proinflammatory mediators as 
well as by measuring cells and mediators released during the 
early and late phases of allergic reactions.
3 However, the prim-
ing effect of the nasal mucosa is important, because a single 
challenge does not perfectly mimic ongoing allergic reactions Roles of Periostin in Allergic Rhinitis
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induced by repeated allergen exposure. In intermittent and 
persistent AR, the same cells and mediators are important, but 
non-specific nasal hyperreactivity develops.
3 Based on symp-
tom scores, it is conceivable that periostin deficiency in this 
chronic AR model may reduce inflammation and remodeling.
In conclusion, periostin was expressed in the nasal tissue in a 
chronic murine model of AR. Periostin deficiency affected the 
remodeling of the nasal tissue with reduced subepithelial fibro-
sis. Eosinophilic inflammation in the nasal tissue was decreased 
in periostin-deficient mice. However, more research remains to 
be done on the molecular mechanism of remodeling without 
periostin and on acute Th2 cell-associated inflammation with-
out periostin before this protein can be used to treat AR in clini-
cal practice.
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